BACKGROUND: Bone metastases occur frequently in patients with solid tumours such as those of the prostate, breast and lung, and are associated with an increased risk of skeletal-related events (SREs). This article reviews the personal, social and economic burdens of bone metastases and SREs, and approaches to treatment. METHODS: PubMed searches were conducted using a broad range of search terms. Articles identified were refined by author review of abstracts. Additional material was identified by searching recent relevant congress abstracts. RESULTS: Bone metastases often decrease quality of life, but quantitative data on the extent of this effect are limited. Data from the USA demonstrate a significant financial burden associated with bone metastases; similar trends are now being uncovered in Europe as the number of assessments of health economics and healthcare resource utilisation in the region increases. The bisphosphonate zoledronic acid reduces the incidence of SREs compared with placebo. Recent phase 3 studies have shown that therapy with the RANK ligand inhibitor denosumab is superior to zoledronic acid for preventing or delaying SREs in patients with bone metastases from solid tumours. Denosumab also has a comparable safety profile to bisphosphonates, with reduced risk of renal toxicity and acute phase reactions. Data from Europe suggest that denosumab is cost-effective for the prevention of SREs compared with zoledronic acid. Additionally, several new experimental bone-targeted agents show promise. CONCLUSION: Recent progress may help to reshape evidence-based guidelines to improve patient care and reduce the economic burden of bone metastases.
BACKGROUND:Bone metastases occur frequently in patients with solid tumours such as those of the prostate, breast and lung, and are associated with an increased risk of skeletal-related events (SREs). This article reviews the personal, social and economic burdens of bone metastases and SREs, and approaches to treatment. METHODS: PubMed searches were conducted using a broad range of search terms. Articles identified were refined by author review of abstracts. Additional material was identified by searching recent relevant congress abstracts. RESULTS:Bone metastases often decrease quality of life, but quantitative data on the extent of this effect are limited. Data from the USA demonstrate a significant financial burden associated with bone metastases; similar trends are now being uncovered in Europe as the number of assessments of health economics and healthcare resource utilisation in the region increases. The bisphosphonatezoledronic acid reduces the incidence of SREs compared with placebo. Recent phase 3 studies have shown that therapy with the RANK ligand inhibitor denosumab is superior to zoledronic acid for preventing or delaying SREs in patients with bone metastases from solid tumours. Denosumab also has a comparable safety profile to bisphosphonates, with reduced risk of renal toxicity and acute phase reactions. Data from Europe suggest that denosumab is cost-effective for the prevention of SREs compared with zoledronic acid. Additionally, several new experimental bone-targeted agents show promise. CONCLUSION: Recent progress may help to reshape evidence-based guidelines to improve patient care and reduce the economic burden of bone metastases.
Authors: Arjun Sahgal; Mark Bilsky; Eric L Chang; Lijun Ma; Yoshiya Yamada; Laurence D Rhines; Daniel Létourneau; Matthew Foote; Eugene Yu; David A Larson; Michael G Fehlings Journal: J Neurosurg Spine Date: 2010-12-24
Authors: Thomas Delea; Corey Langer; James McKiernan; Martin Liss; John Edelsberg; Jane Brandman; Jennifer Sung; Monika Raut; Gerry Oster Journal: Oncology Date: 2004 Impact factor: 2.935
Authors: Lee S Rosen; David Gordon; N Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; Maciej Krzakowski; Marek Pawlicki; Paul De Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John Seaman Journal: Cancer Date: 2004-06-15 Impact factor: 6.860
Authors: M Aapro; P A Abrahamsson; J J Body; R E Coleman; R Colomer; L Costa; L Crinò; L Dirix; M Gnant; J Gralow; P Hadji; G N Hortobagyi; W Jonat; A Lipton; A Monnier; A H G Paterson; R Rizzoli; F Saad; B Thürlimann Journal: Ann Oncol Date: 2007-09-28 Impact factor: 32.976
Authors: Michael Chan; Kristopher Dennis; Yuexi Huang; Charles Mougenot; Edward Chow; Carlo DeAngelis; Jennifer Coccagna; Arjun Sahgal; Kullervo Hynynen; Gregory Czarnota; William Chu Journal: Technol Cancer Res Treat Date: 2016-08-01
Authors: Rohini K Hernandez; Jane Quigley; Melissa Pirolli; David Quach; Kristina S Chen; Jorge Arellano; Alexander Liede Journal: Support Care Cancer Date: 2014-05-02 Impact factor: 3.603
Authors: Gwen McCaffrey; Michelle L Thompson; Lisa Majuta; Michelle N Fealk; Stephane Chartier; Geraldine Longo; Patrick W Mantyh Journal: Cancer Res Date: 2014-10-06 Impact factor: 12.701
Authors: Yi Qian; Jorge Arellano; Francesca Gatta; Guy Hechmati; A Brett Hauber; Ateesha F Mohamed; Amit Bahl; Roger von Moos; Jean-Jacques Body Journal: BMC Health Serv Res Date: 2018-07-03 Impact factor: 2.655
Authors: Roger von Moos; Jean-Jacques Body; Blair Egerdie; Alison Stopeck; Janet Brown; Lesley Fallowfield; Donald L Patrick; Charles Cleeland; Danail Damyanov; Felipe Salvador Palazzo; Gavin Marx; Ying Zhou; Ada Braun; Arun Balakumaran; Yi Qian Journal: Support Care Cancer Date: 2015-09-02 Impact factor: 3.603
Authors: T Lebret; A Casas; M Cavo; P J Woll; C Deleplace; C Kennedy; P Schoen; C Jackisch Journal: Eur J Cancer Care (Engl) Date: 2016-04-12 Impact factor: 2.520